Skip to main content

Table 1 Patient characteristics

From: The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trial

 

No paracetamol intake

(n = 1480)

paracetamol intake

(n = 1166)

p-value

Male sex (n)

73% (1076)

65% (753)

 < 0.001

Age in years

75 (72–79)

75 (72–79)

0.98

70–79 years (n)

80% (1178)

78% (908)

 

80–89 years (n)

19% (286)

21% (248)

 

 > 90 years (n)

1% (16)

1% (10)

 

BMI

27 (25–31)

28 (25–31)

0.93

SOFA Score

5 (3–8)

5 (3–8)

0.004

CFS

3 (2–4)

3 (2–5)

 < 0.001

Comorbidities

 Diabetes mellitus

34% (495)

43% (495)

 < 0.001

 Arterial hypertension

65% (957)

70% (814)

0.006

 CAD

24% (350)

25% (286)

0.61

 Chronic heart failure

14% (210)

15% (177)

0.47

 Pulmonary disease

23% (333)

22% (258)

0.91

 CKD

16% (235)

18% (213)

0.097

  1. Abbreviations: BMI Body mass index (kg/m2), CAD Coronary artery disease, CFS Clinical Frailty Scale, CKD Chronic kidney disease, IQR Interquartile range, SD Standard deviation, SOFA Sequential Organ Failure Assessment
  2. Categorical variables displayed as % (n), continuous variables as median (IQR). Patients with reported paracetamol intake had a higher SOFA Score on ICU admission than those without paracetamol intake